Updates Center

• 
  COMPANY ANNOUNCEMENT

  AtaGenix Laboratories Co., Ltd. issues a formal statement addressing the unauthorized use of its name by Wuhan Biolab-reagent, which forged documents and official seals, constituting illegal activity and unfair competition. The company clarifies that no business agreements exist with Wuhan Biolab-reagent, condemns their actions, and reserves the right to pursue legal action under Chinese intellectual property and criminal laws. AtaGenix advises partners to verify document authenticity to avoid legal and financial risks, reaffirming its commitment to honest operation and industry fairness.
• 
  International Life Sciences Leaders Visit AtaGenix: Advancing Antibody R&D with Velocity and Rigor

  On October 14, 2025, AtaGenix in Wuhan, China, welcomed global life sciences representatives to explore its 6-month antibody R&D platform, marking a biotech collaboration milestone.
• 
  AtaGenix at AACR 2026 | Custom Antibody Development & abinScience Reagents

  AtaGenix showcased custom antibody development services and the abinScience catalog of 35,000+ research reagents at AACR 2026 Booth #1761 in San Diego. Explore antibodies, recombinant proteins, ELISA kits, in vivo antibodies, and anti-idiotype antibodies for oncology and drug development research.
• 
  AtaGenix at Pivotal Links 2026 | Gold Sponsor | Oxford, UK

  AtaGenix Laboratories will attend Pivotal Links 2026 in Oxford as Gold Sponsor, showcasing custom antibody development services and the abinScience catalog of 35,000+ research reagents. Schedule a meeting with our team.
• 
  AtaGenix September 2026 Publication Roundup: Ten Studies Across Oncology, Immunology and Pathogen Research

  Ten studies supported by AtaGenix were published in September 2026 in journals including Cell Death & Disease, Cell Communication and Signaling, Materials Today Bio, PLOS Pathogens and mBio. The research spans triple-negative breast cancer, glioblastoma, rice photosynthesis, pollen allergy, systemic lupus erythematosus, pangolin-derived sarbecoviruses, grass carp reovirus, Edwardsiella infection, tick-borne encephalitis virus and age-related macular degeneration. Across these projects AtaGenix provided recombinant proteins, custom polyclonal and monoclonal antibodies, site-specific phospho-antibodies, synthetic peptides and expression plasmid construction, supplying the reagents on which key mechanistic and functional experiments were built.
• 
  AtaGenix to Exhibit at analytica China 2026 — Visit Us at Booth N5-5159

  AtaGenix showcases its Xten™ Mab single B cell antibody discovery platform and 38,000+ abinScience catalog reagents at analytica China 2026, Booth N5-5159, November 16–18, Shanghai.
• 
  AtaGenix June Research Highlights: Five Publications Spanning Archaea, Pest Control, Monkeypox Diagnostics, and Aquaculture

  In June, five research teams publishing in journals including Nucleic Acids Research, Journal of Analysis and Testing, Entomologia Generalis, Microbiology Spectrum, and Marine Biotechnology acknowledged AtaGenix's technical contributions. AtaGenix-produced custom polyclonal antibodies supported cell cycle studies in the archaeon Saccharolobus islandicus and pest resistance research in the diamondback moth; rabbit immunization services underpinned monoclonal antibody development for nicosulfuron residue detection; antibody sequencing services facilitated monkeypox virus diagnostic platform development; and a custom Amh antibody enabled immunofluorescence characterization of sex reversal in Yellow River carp. Across disciplines, AtaGenix delivered end-to-end antibody and immunization solutions that proved central to each study's experimental findings.
• 
  AtaGenix May 2026 Research Highlights: Five Landmark Studies Published Across Neurodegeneration, Virology, and Immunology

  In May 2026, AtaGenix supported five studies published in leading journals including Translational Neurodegeneration and the Journal of Medical Virology. Research spanned Alzheimer's disease tau pathology, pollen allergy immunotherapy, atherosclerosis drug discovery, AQP4-targeted herbal medicine screening, and RSV subunit vaccine evaluation. In each case, AtaGenix delivered purpose-built reagents — custom antibodies and recombinant proteins — that were central to key experimental workflows, driving discoveries from bench to publication.
• 
  VINS Visits AtaGenix Wuhan HQ for Biopharma Partnership

  On June 25, 2025, VINS Bioproducts visited AtaGenix’s Wuhan headquarters to expand collaboration on vaccine raw materials, antibody R&D, and CRO services—advancing public health and innovation.
• 
  AtaGenix Excels at Thailand LAB International 2025: Pioneering Antibody Discovery & Protein Expression

  AtaGenix Laboratories Co., Ltd. participated in Thailand LAB International 2025 in Bangkok from September 3-5, showcasing advanced antibody discovery and protein expression technologies at booth 2S21. Through technical exhibits, seminars, and business discussions, AtaGenix established global partnerships, reinforcing its leadership in the Asia-Pacific biotechnology market.